Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Palvella Therapeutics, Inc. logoPalvella Therapeutics, Inc.

PVLA · Nasdaq · USD · Market cap $2.1B · 29 employees

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

FAIL · Does not pass the screen
142.85 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price142.85 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.22)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $207.00 to $267.00, base estimate $232.00 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders insiders sold, $537,307, latest filing 2026-10-21
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.22, read 2026-11-15
  • Ethical does not pass the values gate
Price142.85 USD
Fair value232.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup163.94-12.9% to today Accumulation gives way to Markup after a 12% rise in 11 days
2026-11-01Read Accumulation146.15-2.3% to today Markdown gives way to Accumulation with results news in the headlines
2026-09-10Read Markdown150.33-5.0% to today ✓Markup gives way to Markdown
2026-08-09Read Markup157.24-9.2% to today Distribution gives way to Markup after a 45% rise in 5 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Palvella Therapeutics, Inc. holds its Markup at $142.85. Elevated stress, defensive posture warranted, held for 64 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateElevated stress, defensive posture warranted, held for 64 days
Price at the screen$142.85
ValuationN/A trailing · -18.57 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens: PVLA's Results

FAIL. Accounts receivable

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 1.06% Below 33% Pass
Interest-bearing cash 0.00% Below 33% Pass
Receivables 97.35% Below 49% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Palvella Therapeutics,'s business is fine, but its receivables are about 97% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when PVLA's ethical verdict changes

Today PVLA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 38% discount to our $232.00 fair value.

Method.

207.00Conservative232.00Base case267.00Growth case 142.85Price

USD, 2026-11-20 screen. A 38.4% under base.

The Street's Range
207.00Street low 232.00Street average 267.00Street high 142.85Price

Street: 16 covering, consensus Strong Buy. Average target +62%.

Chart
The Business, in Plain Words

Rare skin drugs face long clinical odds

A clinical-stage US biotech chasing topical treatments for rare genetic skin diseases sits at a price well below its stated fair value. Yet the opportunity rating lands at none because the ethical screen flags insufficient data on basic financial ratios. That alone stops any deeper look.

The business shows zero profit margins, a sharply negative return on equity and a forward price-to-earnings ratio deep in the red. With no commercial products and an unknown competitive moat, the numbers point to years of cash burn before any revenue arrives.

Risks centre on trial setbacks, repeated equity raises and the complete lack of ethical data to assess governance or supply-chain issues. Fifteen analysts list a higher median target but offer no consensus rating to rely on. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-18.6x
EPS, trailing-5.53
EPS, forward-7.77
Profit margin0.0%currently unprofitable
Return on equity-63.4%not currently earning a positive return on equity
FCF yield-1.33%
Debt to equity0.13minimal debt: a conservative balance sheet
Current ratio16.01comfortably covers its short-term bills
Short interest, float0.20%
52-week range72.23 - 179.95
Market cap$2.1B
Employees29

PVLA-specific watchpoints · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $146.58 +0.0% Entry 18
2026-11-19 Markup $146.58 -10.6% Entry 17
2026-11-12 Markup · changed $163.94 +1.0% Entry 16

The framework has shifted from accumulation to markup since the last review.

2026-11-05 Accumulation $162.28 +6.1% Entry 15
2026-11-04 Accumulation $152.93 +4.6% Entry 14
2026-11-03 Accumulation $146.15 +0.0% Entry 13
2026-11-02 Accumulation $146.15 +0.0% Entry 12
2026-11-01 Accumulation · changed $146.15 +16.8% Entry 11

The framework has shifted from markdown to accumulation since the last review.

2026-10-31 Markdown $125.10 +0.0% Entry 10
2026-10-30 Markdown $125.10 -1.2% Entry 9

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on PVLA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in PVLA's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · PVLA
DateInsiderTitleTypeSharesValue
2026-10-21 Goin Kathleen COO S - Sale+OE 4,313 $537,307
2026-10-12 Jenkins George M Dir S - Sale 27,500 $3,579,476

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $122.09 -16.3% · $837 -16.3%
2 months $127.12 -19.6% · $804 -19.6%
3 months $136.60 -25.2% · $748 -25.2%
6 months $96.78 +5.6% · $1,056 +5.6%
1 year $26.23 +289.5% · $3,895 +289.5%
2 years $10.01 +920.7% · $10,207 +920.7%
3 years $72.80 +40.3% · $1,403 +40.3%
5 years $278.40 -63.3% · $367 -63.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever PVLA does next, these words stay.

Palvella Therapeutics, Inc. · PVLA · Markup · $142.85
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.